Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT05559853
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • Brain Metastases, Adult
  • Metastatic Brain Cancer
  • Metastatic Brain Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • CEST-MRF — DIAGNOSTIC_TEST
    CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.

Study Details

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

Key Dates

Start date
Sep 22, 2022
Status verified
Mar 2026
Primary completion
Sep 22, 2027
Completion
Sep 22, 2027

Study Design

Enrollment
119 participants (estimated)

Arms

  • Arm: Participants with Brain Metastases
    Participants will have at least one untreated brain metastasis \> 1cm
  • Arm: Healthy participants
    Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.

Primary Outcome Measure

Change of Rapid chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF)/CEST-MRF parameters with and without motion [ Time Frame: Up to 3 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Ouri Coheb, PhD
[email protected]
646-608-8259

Find similar trials in New York, NY

By research site
Memorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies